{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["COVID-19", "SARS-CoV-2", "Saudi Arabia", "antiviral activity", "glycyrrhizic acid", "licorice"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34959616", "DateRevised": {"Year": "2024", "Month": "04", "Day": "04"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "11", "Day": "24"}], "Language": ["eng"], "ELocationID": ["1216", "10.3390/ph14121216"], "Journal": {"ISSN": "1424-8247", "JournalIssue": {"Volume": "14", "Issue": "12", "PubDate": {"Year": "2021", "Month": "Nov", "Day": "24"}}, "Title": "Pharmaceuticals (Basel, Switzerland)", "ISOAbbreviation": "Pharmaceuticals (Basel)"}, "ArticleTitle": "Computational and In Vitro Experimental Investigations Reveal Anti-Viral Activity of Licorice and Glycyrrhizin against Severe Acute Respiratory Syndrome Coronavirus 2.", "Abstract": {"AbstractText": ["Without effective antivirals, the COVID-19 pandemic will likely continue to substantially affect public health. Medicinal plants and phytochemicals are attractive therapeutic options, particularly those targeting viral proteins essential for replication cycle. Herein, a total 179 phytochemicals of licorice (Glycyrrhiza glabra) were screened and scrutinized against the SARS-CoV-2 main protease (M<sup>pro</sup>) with considerable binding affinities in the range of -9.831 to -2.710 kcal/mol. The top 10 compounds with the best docking scores, licuraside, glucoliquiritin apioside, 7,3'-Dihydroxy-5'-methoxyisoflavone, licuroside, kanzonol R, neoisoliquiritin, licochalcone-A, formononetin, isomucronulatol, and licoricone, were redocked using AutoDock Vina, yielding -8.7 to -7.3 kcal/mol binding energy against Glycyrrhizin (-8.0 kcal/mol) as a reference ligand. Four compounds, licuraside, glucoliquiritin apioside, 7,3'-Dihydroxy-5'-methoxyisoflavone, and licuroside, with glycyrrhizin (reference ligand) were considered for the 100 ns MD simulation and post-simulation analysis which support the stability of docked bioactive compounds with viral protein. In vitro studies demonstrated robust anti-SARS-CoV-2 activity of licorice and glycyrrhizin under different treatment protocols (simulations treatment with viral infection, post-infection treatment, and pre-treatment), suggesting multiple mechanisms for action. Although both compounds inhibited SARS-CoV-2 replication, the half-maximal inhibitory concentration (IC50) of glycyrrhizin was substantially lower than licorice. This study supports proceeding with in vivo experimentation and clinical trials and highlights licorice and glycyrrhizin as potential therapeutics for COVID-19."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 128442, Jeddah 21362, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, P.O. Box 21911, Rabigh 344, Saudi Arabia."}], "LastName": "Tolah", "ForeName": "Ahmed M", "Initials": "AM"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 128442, Jeddah 21362, Saudi Arabia."}], "LastName": "Altayeb", "ForeName": "Lamya M", "Initials": "LM"}, {"Identifier": ["0000-0001-9130-4031"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 128442, Jeddah 21362, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia."}], "LastName": "Alandijany", "ForeName": "Thamir A", "Initials": "TA"}, {"Identifier": ["0000-0003-0767-1328"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center for Bioinformatics, Computational and System Biology, Pathfinder Research and Training Foundation, Greater Noida 201308, India."}], "LastName": "Dwivedi", "ForeName": "Vivek Dhar", "Initials": "VD"}, {"Identifier": ["0000-0002-3667-7529"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 128442, Jeddah 21362, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia."}], "LastName": "El-Kafrawy", "ForeName": "Sherif A", "Initials": "SA"}, {"Identifier": ["0000-0002-1736-181X"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Special Infectious Agents Unit, King Fahd Medical Research Center, King Abdulaziz University, P.O. Box 128442, Jeddah 21362, Saudi Arabia."}, {"Identifier": [], "Affiliation": "Department of Medical Laboratory Technology, Faculty of Applied Medical Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia."}], "LastName": "Azhar", "ForeName": "Esam I", "Initials": "EI"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Pharmaceuticals (Basel)", "NlmUniqueID": "101238453", "ISSNLinking": "1424-8247"}, "CoiStatement": "The authors declare no conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Bharadwaj S., Dubey A., Yadava U., Mishra S.K., Kang S.G., Dwivedi V.D. Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro. Brief. Bioinform. 2021;22:1361\u20131377. doi: 10.1093/bib/bbaa382.", "ArticleIdList": ["10.1093/bib/bbaa382", "PMC7929395", "33406222"]}, {"Citation": "Bharadwaj S., El-Kafraway S.A., Alandijany T.A., Bajrai L.H., Shah A.A., Dubey A., Sahoo A.K., Yadava U., Kamal M.A., Azhar E.I., et al. Structure-Based Identification of Natural Products as SARS-CoV-2 M(pro) Antagonist from Echinacea angustifolia Using Computational Approaches. Viruses. 2021;13:305. doi: 10.3390/v13020305.", "ArticleIdList": ["10.3390/v13020305", "PMC7919488", "33672054"]}, {"Citation": "Bharadwaj S., Azhar E.I., Kamal M.A., Bajrai L.H., Dubey A., Jha K., Yadava U., Kang S.G., Dwivedi V.D. SARS-CoV-2 M(pro) inhibitors: Identification of anti-SARS-CoV-2 M(pro) compounds from FDA approved drugs. J. Biomol. Struct. Dyn. 2020;38:1\u201316. doi: 10.1080/07391102.2020.1842807.", "ArticleIdList": ["10.1080/07391102.2020.1842807", "PMC7651494", "33150855"]}, {"Citation": "Jarvis M.C. Aerosol Transmission of SARS-CoV-2: Physical Principles and Implications. Front. Public Health. 2020;8:590041. doi: 10.3389/fpubh.2020.590041.", "ArticleIdList": ["10.3389/fpubh.2020.590041", "PMC7719704", "33330334"]}, {"Citation": "Kembuan G., Lie W., Tumimomor A. Potential usage of immune modulating supplements of the Echinacea genus for COVID-19 infection. Int. J. Med. Rev. Case Rep. 2020;4:203\u2013217. doi: 10.5455/IJMRCR.immune-modulating-supplements-Echinacea-genus-covid-19-infection.", "ArticleIdList": ["10.5455/IJMRCR.immune-modulating-supplements-Echinacea-genus-covid-19-infection"]}, {"Citation": "Beigel J.H., Tomashek K.M., Dodd L.E., Mehta A.K., Zingman B.S., Kalil A.C., Hohmann E., Chu H.Y., Luetkemeyer A., Kline S., et al. Remdesivir for the Treatment of COVID-19-Final Report. N. Engl. J. Med. 2020;383:1813\u20131826. doi: 10.1056/NEJMoa2007764.", "ArticleIdList": ["10.1056/NEJMoa2007764", "PMC7262788", "32445440"]}, {"Citation": "Caly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antivir. Res. 2020;178:104787. doi: 10.1016/j.antiviral.2020.104787.", "ArticleIdList": ["10.1016/j.antiviral.2020.104787", "PMC7129059", "32251768"]}, {"Citation": "Arya A., Dwivedi V.D. Synergistic effect of vitamin D and remdesivir can fight COVID-19. J. Biomol. Struct. Dyn. 2020;8:1\u20132. doi: 10.1080/07391102.2020.1773929.", "ArticleIdList": ["10.1080/07391102.2020.1773929", "32456606"]}, {"Citation": "Bharadwaj S., Lee K.E., Dwivedi V.D., Kang S.G. Computational insights into tetracyclines as inhibitors against SARS-CoV-2 M(pro) via combinatorial molecular simulation calculations. Life Sci. 2020;257:118080. doi: 10.1016/j.lfs.2020.118080.", "ArticleIdList": ["10.1016/j.lfs.2020.118080", "PMC7347340", "32653520"]}, {"Citation": "SSalian V.S., Wright J.A., Vedell P.T., Nair S., Li C., Kandimalla M., Tang X., Carmona Porquera E.M., Kalari K.R., Kandimalla K.K. COVID-19 Transmission, Current Treatment, and Future Therapeutic Strategies. Mol. Pharm. 2021;18:754\u2013771. doi: 10.1021/acs.molpharmaceut.0c00608.", "ArticleIdList": ["10.1021/acs.molpharmaceut.0c00608", "33464914"]}, {"Citation": "Naqvi A.A., Fatima K., Mohammad T., Fatima U., Singh I.K., Singh A., Atif S.M., Hariprasad G., Hasan G.M., Hassan M.I. Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: Structural genomics approach. Biochim. Biophys. Acta Mol. Basis Dis. 2020;1866:165878. doi: 10.1016/j.bbadis.2020.165878.", "ArticleIdList": ["10.1016/j.bbadis.2020.165878", "PMC7293463", "32544429"]}, {"Citation": "V\u2019Kovski P., Kratzel A., Steiner S., Stalder H., Thiel V. Coronavirus biology and replication: Implications for SARS-CoV-2. Nat. Rev. Microbiol. 2021;19:155\u2013170. doi: 10.1038/s41579-020-00468-6.", "ArticleIdList": ["10.1038/s41579-020-00468-6", "PMC7592455", "33116300"]}, {"Citation": "Liu X.H., Zhang X., Lu Z.H., Zhu Y.S., Wang T. Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection. Biomed. Pharmacother. 2021;133:111035. doi: 10.1016/j.biopha.2020.111035.", "ArticleIdList": ["10.1016/j.biopha.2020.111035", "PMC7671653", "33254013"]}, {"Citation": "Ullrich S., Nitsche C. The SARS-CoV-2 main protease as drug target. Bioorganic Med. Chem. Lett. 2020;30:127377. doi: 10.1016/j.bmcl.2020.127377.", "ArticleIdList": ["10.1016/j.bmcl.2020.127377", "PMC7331567", "32738988"]}, {"Citation": "Jin Z., Du X., Xu Y., Deng Y., Liu M., Zhao Y., Zhang B., Li X., Zhang L., Peng C., et al. Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors. Nature. 2020;582:289\u2013293. doi: 10.1038/s41586-020-2223-y.", "ArticleIdList": ["10.1038/s41586-020-2223-y", "32272481"]}, {"Citation": "Zhang L., Lin D., Sun X., Curth U., Drosten C., Sauerhering L., Becker S., Rox K., Hilgenfeld R. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science. 2020;368:409\u2013412. doi: 10.1126/science.abb3405.", "ArticleIdList": ["10.1126/science.abb3405", "PMC7164518", "32198291"]}, {"Citation": "Dai W., Zhang B., Jiang X.M., Su H., Li J., Zhao Y., Xie X., Jin Z., Peng J., Liu F., et al. Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease. Science. 2020;368:1331\u20131335. doi: 10.1126/science.abb4489.", "ArticleIdList": ["10.1126/science.abb4489", "PMC7179937", "32321856"]}, {"Citation": "Dwivedi V.D., Bharadwaj S., Afroz S., Khan N., Ansari M.A., Yadava U., Tripathi R.C., Tripathi I.P., Mishra S.K., Kang S.G. Anti-dengue infectivity evaluation of bioflavonoid from Azadirachta indica by dengue virus serine protease inhibition. J. Biomol. Struct. Dyn. 2021;39:1417\u20131430. doi: 10.1080/07391102.2020.1734485.", "ArticleIdList": ["10.1080/07391102.2020.1734485", "32107969"]}, {"Citation": "Armanini D., Fiore C., Bielenberg J., Sabbadin C., Bordin L. Coronavirus-19: Possible Therapeutic Implications of Spironolactone and Dry Extract of Glycyrrhiza glabra L. (Licorice) Front. Pharmacol. 2020;11:558418. doi: 10.3389/fphar.2020.558418.", "ArticleIdList": ["10.3389/fphar.2020.558418", "PMC7642094", "33192504"]}, {"Citation": "Sinha S.K., Prasad S.K., Islam M.A., Gurav S.S., Patil R.B., AlFaris N.A., Aldayel T.S., AlKehayez N.M., Wabaidur S.M., Shakya A. Identification of bioactive compounds from Glycyrrhiza glabra as possible inhibitor of SARS-CoV-2 spike glycoprotein and non-structural protein-15: A pharmacoinformatics study. J. Biomol. Struct. Dyn. 2020;17:1\u201315. doi: 10.1080/07391102.2020.1779132.", "ArticleIdList": ["10.1080/07391102.2020.1779132", "PMC7309308", "32552462"]}, {"Citation": "Gomaa A.A., Abdel-Wadood Y.A. The potential of glycyrrhizin and licorice extract in combating COVID-19 and associated conditions. Phytomed. Plus. 2021;1:100043. doi: 10.1016/j.phyplu.2021.100043.", "ArticleIdList": ["10.1016/j.phyplu.2021.100043", "PMC7886629", "35399823"]}, {"Citation": "Fukuchi K., Okudaira N., Adachi K., Odai-Ide R., Watanabe S., Ohno H., Yamamoto M., Kanamoto T., Terakubo S., Nakashima H., et al. Antiviral and Antitumor Activity of Licorice Root Extracts. In Vivo. 2016;30:777\u2013785. doi: 10.21873/invivo.10994.", "ArticleIdList": ["10.21873/invivo.10994", "27815461"]}, {"Citation": "Fiore C., Eisenhut M., Krausse R., Ragazzi E., Pellati D., Armanini D., Bielenberg J. Antiviral effects of Glycyrrhiza species. Phytother. Res. 2008;22:141\u2013148. doi: 10.1002/ptr.2295.", "ArticleIdList": ["10.1002/ptr.2295", "PMC7167979", "17886224"]}, {"Citation": "Zhang L., Liu Y. Potential interventions for novel coronavirus in China: A systematic review. J. Med. Virol. 2020;92:479\u2013490. doi: 10.1002/jmv.25707.", "ArticleIdList": ["10.1002/jmv.25707", "PMC7166986", "32052466"]}, {"Citation": "Yu S., Zhu Y., Xu J., Yao G., Zhang P., Wang M., Zhao Y., Lin G., Chen H., Chen L., et al. Glycyrrhizic acid exerts inhibitory activity against the spike protein of SARS-CoV-2. Phytomedicine. 2021;85:153364. doi: 10.1016/j.phymed.2020.153364.", "ArticleIdList": ["10.1016/j.phymed.2020.153364", "PMC7531286", "33041173"]}, {"Citation": "Tsui V., Case D.A. Theory and applications of the generalized Born solvation model in macromolecular simulations. Biopolymers. 2000;56:275\u2013291. doi: 10.1002/1097-0282(2000)56:4<275::AID-BIP10024>3.0.CO;2-E.", "ArticleIdList": ["10.1002/1097-0282(2000)56:4<275::AID-BIP10024>3.0.CO;2-E", "11754341"]}, {"Citation": "Ngo S.T., Tam N.M., Quan P.M., Nguyen T.H. A Benchmark of Popular Free Energy Approaches Revealing the Inhibitors Binding to SARS-CoV2 Mpro. J. Chem. Inf. Model. 2020;61:2302\u20132312. doi: 10.1021/acs.jcim.1c00159.", "ArticleIdList": ["10.1021/acs.jcim.1c00159", "33829781"]}, {"Citation": "Kim S., Chen J., Cheng T., Gindulyte A., He J., He S., Li Q., Shoemaker B.A., Thiessen P.A., Yu B., et al. PubChem in 2021: New data content and improved web interfaces. Nucleic Acids Res. 2021;49:D1388\u2013D1395. doi: 10.1093/nar/gkaa971.", "ArticleIdList": ["10.1093/nar/gkaa971", "PMC7778930", "33151290"]}, {"Citation": "Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30:2785\u20132791. doi: 10.1002/jcc.21256.", "ArticleIdList": ["10.1002/jcc.21256", "PMC2760638", "19399780"]}, {"Citation": "O\u2019Boyle N.M., Banck M., James C.A., Morley C., Vandermeersch T., Hutchison G.R. Open Babel: An open chemical toolbox. J. Cheminformatics. 2011;3:33. doi: 10.1186/1758-2946-3-33.", "ArticleIdList": ["10.1186/1758-2946-3-33", "PMC3198950", "21982300"]}, {"Citation": "Dallakyan S., Olson A.J. Small-molecule library screening by docking with PyRx. Methods Mol. Biol. 2015;1263:243\u2013250.", "ArticleIdList": ["25618350"]}, {"Citation": "Trott O., Olson A.J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31:455\u2013461. doi: 10.1002/jcc.21334.", "ArticleIdList": ["10.1002/jcc.21334", "PMC3041641", "19499576"]}, {"Citation": "Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera\u2014A visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25:1605\u20131612. doi: 10.1002/jcc.20084.", "ArticleIdList": ["10.1002/jcc.20084", "15264254"]}, {"Citation": "Bharadwaj S., Lee K.E., Dwivedi V.D., Yadava U., Nees M., Kang S.G. Density functional theory and molecular dynamics simulation support Ganoderma lucidum triterpenoids as broad range antagonist of matrix metalloproteinases. J. Mol. Liq. 2020;311:113322. doi: 10.1016/j.molliq.2020.113322.", "ArticleIdList": ["10.1016/j.molliq.2020.113322"]}, {"Citation": "van de Sand L., Bormann M., Alt M., Schipper L., Heilingloh C.S., Steinmann E., Todt D., Dittmer U., Elsner C., Witzke O., et al. Glycyrrhizin Effectively Inhibits SARS-CoV-2 Replication by Inhibiting the Viral Main Protease. Viruses. 2021;13:609. doi: 10.3390/v13040609.", "ArticleIdList": ["10.3390/v13040609", "PMC8066091", "33918301"]}, {"Citation": "Bowers K.J., Chow D.E., Xu H., Dror R.O., Eastwood M.P., Gregersen B.A., Klepeis J.L., Kolossvary I., Moraes M.A., Sacerdoti F.D. Scalable algorithms for molecular dynamics simulations on commodity clusters; Proceedings of the SC\u201906 ACM/IEEE Conference on Supercomputing; Tampa, FL, USA. 11\u201317 November 2006."}, {"Citation": "Azhar E.I., Hindawi S.I., El-Kafrawy S.A., Hassan A.M., Tolah A.M., Alandijany T.A., Bajrai L.H., Damanhouri G.A. Amotosalen and ultraviolet A light treatment efficiently inactivates severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human plasma. Vox Sang. 2021;116:673\u2013681. doi: 10.1111/vox.13043.", "ArticleIdList": ["10.1111/vox.13043", "PMC8359189", "33277935"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "10", "Day": "19"}, {"Year": "2021", "Month": "11", "Day": "15"}, {"Year": "2021", "Month": "11", "Day": "17"}, {"Year": "2021", "Month": "12", "Day": "28", "Hour": "1", "Minute": "4"}, {"Year": "2021", "Month": "12", "Day": "29", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "12", "Day": "29", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "11", "Day": "24"}], "PublicationStatus": "epublish", "ArticleIdList": ["34959616", "PMC8703534", "10.3390/ph14121216", "ph14121216"]}}], "PubmedBookArticle": []}